Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Chamorey

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2020
Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric studyDorian Culié, Quentin Lisan, Charlotte Leroy, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2020
Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric studyDorian Culié, Quentin Lisan, Charlotte Leroy, et al.
Plos One|May 9, 2017
New advances in DPYD genotype and risk of severe toxicity under capecitabineMarie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2014
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)Franck Bonnetain, Bert Bonsing, Thierry Conroy, et al.
Pageof 16